Research Article

A Retrospective Observational Study on Disease Characteristics and Treatment Patterns of Giant Cell Tumor of the Bone in China

Table 4

Postoperative recurrence-free survival for primary GCTB diagnosis (EAS).

ItemEvent, (%)Event censored, (%)Median time to recurrence (months)2-year recurrence rate (%) (95% CI)

Total627197 (31.4)430 (68.6)75.829.2 (25.3, 33.5)
Sex
 Male322107 (33.2)215 (66.8)72.228.7 (23.5, 34.7)
 Female30590 (29.5)215 (70.5)92.429.7 (24.2, 36.2)
Age group
 <18259 (36.0)16 (64.0)92.431.2 (16.0, 55.0)
 18 to 40475157 (33.1)318 (66.9)72.229.7 (25.3, 34.7)
 >4012731 (24.4)96 (75.6)130.926.9 (18.8, 37.6)
Place of residence
 Beijing11218 (16.1)94 (83.9)NE16.4 (10.0, 26.4)
 Others515179 (34.8)336 (65.2)58.531.8 (27.5, 36.7)
Hospital where GCTB was first diagnosed
 JST43629 (6.7)407 (93.3)NE5.4 (3.3, 8.5)
 Non-JST191168 (88.0)23 (12.0)16.568.0 (61.3, 74.6)
Surgery type
 Curettage442183 (41.4)259 (58.6)45.437.0 (32.1, 42.3)
 Resection18514 (7.6)171 (92.4)NE6.4 (3.3, 12.2)
 Amputation00 (0.0)
 Others00 (0.0)
Target lesion anatomic site
 Axial bone7814 (17.9)64 (82.1)NE17.6 (9.7, 30.7)
 Extremities548183 (33.4)365 (66.6)72.230.8 (26.6, 35.5)

CI = confidence interval; EAS = efficacy analysis set; GCTB = giant cell tumor of the bone; JST = Ji Shui Tan; NE = nonestimable.